Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers

被引:0
作者
Amit Kokate
Xiaoling Li
Bhaskara Jasti
机构
[1] University of the Pacific,Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences
来源
Investigational New Drugs | 2007年 / 25卷
关键词
Caco-2; Albumin; Protein binding; Transport; Fenretinide; Transcellular;
D O I
暂无
中图分类号
学科分类号
摘要
Fenretinide is a synthetic retinoid with chemotherapeutic activity against various malignancies. Upon oral administration to animals, fenretinide was found to be incompletely absorbed and excreted primarily in feces. The purpose of this study was to determine the possible reasons for poor oral absorption of fenretinide using Caco-2 cell monolayers. To achieve this purpose, a solid dispersion of fenretinide with Povidone K25 was used. The apparent permeability coefficient (Papp) of fenretinide across Caco-2 monolayers in the presence of bovine serum albumin (BSA) in the receiver was determined. Apical to basolateral (AP-BL) and basolateral to apical (BL-AP) flux studies were performed to determine the role of an efflux mechanism. In the presence of 4% BSA in the receiver, the Papp was found to be (8.8 ± 0.5) × 10−8 cm/sec. The AP-BL flux increased linearly with an increase in fenretinide concentration (125–640 μM) in the presence of 4% BSA in the receiver. Efflux and paracellular pathways played an insignificant role in the permeability of fenretinide. A significant amount of drug, approximately 13–15% of the initial amount accumulated in the cell membrane. The amount of fenretinide in the donor decreased by 16% over a 3 h period. However, only 0.12% of the initial amount was found in the receiver. Also, the Papp increased with an increase in plasma protein concentration in the receiver. On the basis of these results, the poor permeability of fenretinide can be attributed to its accumulation in the lipophilic cell membrane and poor partitioning into the receiver medium.
引用
收藏
页码:197 / 203
页数:6
相关论文
共 162 条
[1]  
Pollard M(1991)Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide Cancer Res 51 3610-3611
[2]  
Luckert PH(1996)Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide Faseb J 10 1014-1024
[3]  
Sporn MB(1998)Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring Clin Chem 44 420-427
[4]  
Formelli F(1999)Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer J Natl Cancer Inst 91 1847-1856
[5]  
Barua AB(2006)Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann Oncol 17 1065-1071
[6]  
Olson JA(2002)Classical and novel retinoids: their targets in cancer therapy Leukemia 16 463-472
[7]  
Lieberman R(2003)Retinoid therapy of high-risk neuroblastoma Cancer Lett 197 185-192
[8]  
Crowell JA(1980)Pharmacokinetics of N-(4-Hydroxyphenyl)-all- Drug Metab Dispos 8 168-172
[9]  
Hawk ET(2004)-retinamide in rats J Pharmacol Exp Ther 308 438-445
[10]  
Boone CW(2001)Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human J Pharm Sci 90 1015-1025